CRI Celebrates Diversity During 9th Cancer Immunotherapy Month in June En junio, al celebrar el noveno Mes de la inmunoterapia, el Cancer Research Institute conmemora los avances... May 25, 2021July 1, 2022
CRI and RevImmune Announce Dosing of First Patient in New Phase 2 Study First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at... March 30, 2021July 13, 2022
CRI and RevImmune Announce Dosing of First Patient in New Phase 2 Study Primer estudio en probar la IL-7 de RevImmune, un fármaco de interés médico, en pacientes con cáncer... March 30, 2021July 1, 2022
Combination Drug Strategies Gain Ground in PD-1/PD-L1 Pipeline Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report... November 11, 2020July 13, 2022
Jill O’Donnell-Tormey Receives Inaugural Tara Withington Public Service Award Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public... November 11, 2020July 13, 2022
Jill O'Donnell-Tormey recibe el premio inaugural al servicio público Tara Withington La Directora Ejecutiva y Directora de Asuntos Científicos del CRI, Dra. Jill O’Donnell-Tormey, recibe el premio inaugural... November 11, 2020July 1, 2022
